ArticleMedicine2026
A quality improvement initiative for achieving target tacrolimus concentration in renal transplant recipients: A quality improvement article.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tacrolimus is a cornerstone immunosuppressive agent in solid organ transplantation due to its efficacy in preventing rejection. Achieving optimal tacrolimus levels remains challenging and limited studies have explored quality improvement (QI) initiatives aimed at optimizing tacrolimus trough levels. We conducted a QI initiative at Taichung Veterans General Hospital targeting tacrolimus level optimization in renal transplant recipients between January 2015 and January 2019. This multifaceted intervention included: physician reminders integrated into the Electronic Health Information System (EHIS) to monitor trough levels and variability, patient engagement through a mobile application displaying immunosuppressant levels, and automated tacrolimus concentration measurement to reduce ordering errors. Outcomes were descriptively evaluated before and after the interventions, including measurement accuracy, biopsy-proven acute rejection (BPAR) rates, and intrapatient variability (IPV), without formal statistical comparison. The implementation of automated tacrolimus measurement eliminated ordering errors, leading to an estimated cost saving of $78,911.3 over 2 years. A numerical decrease in BPAR incidence was observed, from 9% pre-intervention to 0% post-intervention. Tacrolimus intrapatient variability (IPV) also showed a decreasing trend, from 26.45% in 2019 to 18.7% in 2022. Physician reminders and patient engagement interventions contributed to improved monitoring but had a less pronounced impact on acute rejection rates. This study describes a structured QI initiative, including the automation of tacrolimus concentration measurements, and its association with improvements in therapeutic drug monitoring processes in renal transplant recipients. These findings suggest a potential role for mistake-proofing mechanisms in enhancing measurement accuracy and contributing to cost savings. Observed changes in rejection rates were descriptive and should be interpreted with caution given the small number of events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.